Rubicon Research IPO
Historical offer record. This offer is closed for applications. Prices and subscriptions describe the past offer; GMP observations are unofficial past records, not current quotes or listing predictions.
Data provider: FinAPI. This is a third-party summary, not an official prospectus. Read our data limitations and editorial policy.
No GMP observations are available for this historical offer record. No premium or listing-gain estimate is shown.
Price band
₹461 – ₹485
Lot size
30 shares
Offer application amount
₹14,550
Issue size
₹1377.5 Cr
Historical offer amount for 1 lot at the upper issue price. Confirm the lot size and application terms in the issuer prospectus.
Reported IPO schedule
| Open date | 9 Oct 2025 |
| Close date | 13 Oct 2025 |
| Allotment finalisation | 14 Oct 2025 |
| Refund initiation | 15 Oct 2025 |
| Shares credited to demat | 15 Oct 2025 |
| Reported listing date | 16 Oct 2025 |
Issue size
About Rubicon Research
Rubicon Research is one of the leading pharmaceutical formulations companies and focuses on innovation through dedicated research and development. Moreover, their portfolio includes specialty products and drug-device combination products, aimed mainly at regulated markets, especially the United States.
Company summary supplied by FinAPI. Read the prospectus for the issuer's disclosures and audited financials.
Use of proceeds
| Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company | 310 |
Offer documents and primary references
Read the issuer's offer document and any corrigenda for the full disclosures. A third-party details page is a summary; SEBI filing access does not imply an endorsement of the offer or this website.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.